Should I buy or sell LAVA Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LVTX shares. View LVTX analyst ratings or view top-rated stocks .

What is LAVA Therapeutics' stock price target for 2024?

2 brokerages have issued 1-year price objectives for LAVA Therapeutics' stock. Their LVTX share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 121.4% from the stock's current price. View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts .

How have LVTX shares performed in 2024?

LAVA Therapeutics' stock was trading at $1.58 on January 1st, 2024. Since then, LVTX stock has increased by 71.5% and is now trading at $2.71. View the best growth stocks for 2024 here .

Are investors shorting LAVA Therapeutics?

LAVA Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 211,600 shares, a decline of 34.3% from the March 15th total of 322,100 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 0.1 days. Approximately 1.5% of the shares of the stock are sold short. View LAVA Therapeutics' Short Interest .

When is LAVA Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our LVTX earnings forecast .

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics (NASDAQ:LVTX) announced its earnings results on Wednesday, March, 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by $0.40. The company earned $0.35 million during the quarter, compared to analyst estimates of $25 million. LAVA Therapeutics had a negative trailing twelve-month return on equity of 68.54% and a negative net margin of 620.09%.

When did LAVA Therapeutics IPO?

LAVA Therapeutics (LVTX) raised $100 million in an initial public offering (IPO) on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are LAVA Therapeutics' major shareholders?

LAVA Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.00%).

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LVTX

LAVA Therapeutics (LVTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free LVTX Stock Alerts

$2.71

-0.12 (-4.24%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.64
▼
$2.82
50-Day Range: $1.71
▼
$4.03
52-Week Range: $1.13
▼
$6.47

Volume: 133,347 shs
Average Volume: 289,833 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get LAVA Therapeutics alerts:

LAVA Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 121.4% Upside
$6.00 Price Target
Short Interest: Healthy
1.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.41) to ($1.77) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
LAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
LAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.50% of the float of LAVA Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
LAVA Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in LAVA Therapeutics has recently decreased by 34.31%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
LAVA Therapeutics does not currently pay a dividend.
Dividend Growth
LAVA Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LVTX.

0.0

News and Social Media Coverage

Search Interest
Only 24 people have searched for LVTX on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.79% of the stock of LAVA Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LAVA Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LAVA Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
LAVA Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About LAVA Therapeutics Stock (NASDAQ:LVTX)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LVTX Stock News Headlines

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials

March 20, 2024 | finance.yahoo.com

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 20, 2024 | globenewswire.com

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

March 6, 2024 | finanznachrichten.de

LAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

March 5, 2024 | msn.com

Lava gets $7M from Pfizer as trial for cancer drug advances

March 5, 2024 | globenewswire.com

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

March 1, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 21, 2024 | benzinga.com

LAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest Report

February 14, 2024 | investing.com

LAVA Therapeutics NV (LVTX)

January 25, 2024 | msn.com

Lava signs collaboration agreement with MSD for prostate cancer therapy

January 25, 2024 | seekingalpha.com

PCSA, ONCO and KAVL among mid-day movers

January 25, 2024 | finance.yahoo.com

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

December 13, 2023 | ca.finance.yahoo.com

LAVA Therapeutics N.V. (LVTX)

November 11, 2023 | morningstar.com

LAVA Therapeutics NV LVTX

August 25, 2023 | bizjournals.com

Lava Therapeutics is latest life sciences company to trim its workforce

August 22, 2023 | finanznachrichten.de

LAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

August 22, 2023 | finance.yahoo.com

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

July 6, 2023 | msn.com

LAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34

June 14, 2023 | finanznachrichten.de

LAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

June 14, 2023 | msn.com

Lava Therapeutics shelves hematology drug over competitive concerns

June 12, 2023 | msn.com

HC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy Recommendation

June 9, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on LAVA Therapeutics (LVTX)

June 1, 2023 | finance.yahoo.com

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

May 30, 2023 | finance.yahoo.com

LAVA Announces Annual Meeting of Shareholders

May 30, 2023 | uk.finance.yahoo.com

Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?

See More Headlines

Receive LVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/20/2024
Next Earnings (Estimated): 6/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LVTX
CUSIP: N/A
CIK: 1840748
Web: www.lavatherapeutics.com
Phone: 31-85-016-3100
Fax: N/A
Employees: 69
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +121.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,970,000.00
Net Margins: -620.09%
Pretax Margin: -615.97%
Return on Equity: -68.54%
Return on Assets: -35.68%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 6.62
Quick Ratio: 6.62

Sales & Book Value

Annual Sales: $6.77 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.39 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: 0.64

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Stephen Allen Hurly M.B.A. (Age 56)
M.Sc., CEO, President & Executive Director
Mr. Fred M. Powell CPA (Age 63)
Chief Financial Officer
Dr. Hans van der Vliet M.D. (Age 50)
Ph.D., Chief Scientific Officer
Ms. Amy Garabedian J.D. (Age 48)
General Counsel & Corporate Secretary
Mr. Wouter van Hunnik
VP & Head of Human Resources
Dr. Ton Adang Ph.D. (Age 63)
Chief Development Officer
Dr. Charles Q. Morris M.D. (Age 59)
MBChB, MRCP (UK), Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell LAVA Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LVTX shares.
View LVTX analyst ratings or view top-rated stocks.
What is LAVA Therapeutics' stock price target for 2024?: 2 brokerages have issued 1-year price objectives for LAVA Therapeutics' stock. Their LVTX share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 121.4% from the stock's current price.
View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts.
How have LVTX shares performed in 2024?: LAVA Therapeutics' stock was trading at $1.58 on January 1st, 2024. Since then, LVTX stock has increased by 71.5% and is now trading at $2.71.
View the best growth stocks for 2024 here.
Are investors shorting LAVA Therapeutics?: LAVA Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 211,600 shares, a decline of 34.3% from the March 15th total of 322,100 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 0.1 days. Approximately 1.5% of the shares of the stock are sold short.
View LAVA Therapeutics' Short Interest.
When is LAVA Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024.
View our LVTX earnings forecast.

How were LAVA Therapeutics' earnings last quarter?: LAVA Therapeutics (NASDAQ:LVTX) announced its earnings results on Wednesday, March, 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by $0.40. The company earned $0.35 million during the quarter, compared to analyst estimates of $25 million. LAVA Therapeutics had a negative trailing twelve-month return on equity of 68.54% and a negative net margin of 620.09%.
When did LAVA Therapeutics IPO?: LAVA Therapeutics (LVTX) raised $100 million in an initial public offering (IPO) on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager.
Who are LAVA Therapeutics' major shareholders?: LAVA Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.00%).
How do I buy shares of LAVA Therapeutics?: Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LVTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LAVA Therapeutics (LVTX) Stock Price, News & Analysis

LAVA Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About LAVA Therapeutics Stock (NASDAQ:LVTX)

LVTX Stock Price History

LVTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

LVTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™